Multiple Myeloma Minimal Residual Disease

Comparison of Three Methods to Evaluate Residual Disease in Multiple Myeloma

Three methods including flow cytometry, next generation sequencing and determination of circulating tumor cells will be performed at different time points in patients with previously undiagnosed multiple myeloma in order to determine the most sensitive method to detect residual disease

Inclusion Criteria:

• ≥ 18 years
• previously undiagnosed myeloma
• eligible for high dose therapy and bone marrow transplantation
• signed consent

Exclusion Criteria:

• ongoing therapy for another neoplasia
• Patients with other hematologic malignancies,
• patients deprived of liberty for administrative or judicial reasons
• previously treated for myeloma